Archives
-
Plant Cell Lysis Buffer for WB and IP Workflows
2026-09-07
Build native-state protein workflows for Western blotting, immunoprecipitation, and co-immunoprecipitation from plant or cross-species samples. This guide connects inhibitor-supported extraction with the MAPK10–KRT16 mechanism while clearly separating product-enabled sample preparation from disease-specific biological conclusions.
-
Z-DEVD-FMK: Reading Apoptosis Beyond Caspase-3
2026-09-05
Z-DEVD-FMK is more than a routine caspase-3 inhibitor: its irreversible, cell-permeable activity also intersects with broader caspase signaling and calpain-mediated proteolysis. This thought-leadership guide shows how translational researchers can use it to interpret apoptosis assays, validate melanoma findings, and design better neuroprotection studies without overstating pathway specificity.
-
AP2-M Regulates Babesia Asexual Replication
2026-09-04
This study identifies AP2-M, an Apicomplexan AP2-family transcription factor in Babesia sp. Xinjiang, as a regulator of genes associated with red blood cell invasion, merozoite morphology, and cell-cycle progression. By integrating CUT&Tag, RNA sequencing, proteomics, and single-cell RNA sequencing after AP2-M disruption, the authors connect DNA occupancy with parasite phenotypes and transcriptional state.
-
MG-262: Proteasome Inhibition Workflows
2026-09-04
MG-262 enables controlled, reversible disruption of proteasome chymotryptic activity for ubiquitin-proteasome, apoptosis, and cell-cycle experiments. This workflow connects acute proteostasis stress with the skeletal-muscle CMA findings reported in the reference study while clearly separating what MG-262 can test from what requires dedicated CMA assays.
-
E-64 in Salt-Sensitive Hypertension: Study Analysis
2026-09-03
The reference study tested whether chronic inhibition of cysteine cathepsins alters hypertension, albuminuria, kidney injury, or podocyte calcium handling in Dahl salt-sensitive rats. E-64 did not improve these endpoints under the experimental conditions, demonstrating that cathepsin activity may not be a dominant modifiable driver in this model despite evidence of target engagement.
-
MLN2238: Precision Proteasome β5 Inhibition
2026-09-03
MLN2238 enables controlled, reversible chymotrypsin-like proteasome inhibition for apoptosis, proteostasis, and drug-resistance studies. Its strong β5-site preference supports focused oncology assays, while carefully designed stress-response workflows extend its value to CRTC–CREB research.
-
LTI6426 Enhances Panobinostat in Multiple Myeloma
2026-09-02
The reference study shows that the protein disulfide isomerase inhibitor LTI6426 substantially improves panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant setting. Its central contribution is a dose-sparing combination strategy linked to coordinated induction of the ER-stress effectors ATF3, DDIT3/CHOP, and DNAJB1.
-
Immunoproteasome Activation Reprograms Human TRIM5α
2026-09-02
Jimenez-Guardeño and colleagues show that interferon-α can activate human TRIM5α against HIV-1 by remodeling the immunoproteasome and accelerating TRIM5α turnover. Their siRNA, reporter-virus, and CRISPR validation strategy provides a useful framework for studying how cellular proteostasis regulates antiviral restriction factors.
-
Disulfiram at the Proteasome–Pyroptosis Interface
2026-09-01
Disulfiram is moving from a legacy anti-alcoholism medicine to a strategically useful research probe spanning copper-dependent proteasome biology, cancer cell death, and inflammasome signaling. This article examines what is established, what remains hypothesis-driven, and how translational researchers can design more informative studies.
-
Hypoxia, Immunometabolism, and Tumor Immune Escape
2026-09-01
This 2025 Cancer Letters review presents tumor hypoxia as a systems-level driver of metabolic competition, immune dysfunction, and immunosuppressive microenvironment formation. Its main practical contribution is a framework for connecting oxygen gradients, tumor and immune-cell metabolism, cellular communication, and therapeutic strategy design.
-
Dovitinib (TKI-258) for RTK Cancer Assays
2026-08-31
Dovitinib (TKI-258) supports a practical workflow that connects multitargeted RTK inhibition with ERK, STAT3, STAT5, and apoptosis readouts. This guide shows how to design reproducible viability and signaling experiments, apply the compound in multiple myeloma and hepatocellular carcinoma research, and troubleshoot solubility, timing, and assay-interpretation problems.
-
Phosphosignal Integrity in Translational Toxicology
2026-08-31
Mechanistic toxicology depends on preserving the phosphorylation states that define signaling networks. This thought-leadership article connects lanthanum-induced hepatic steatosis with rigorous sample handling and shows how a dual-component Phosphatase Inhibitor Cocktail can strengthen translational validation without overstating what ex vivo phosphoprotein measurements can prove.
-
Trelagliptin and Insulin Resistance in Adipocytes
2026-08-30
The reference study shows that trelagliptin succinate improves insulin resistance in differentiated 3T3-L1 adipocytes by strengthening the PI-3K/AKT/GLUT4 signaling axis. Its integrated analysis of glucose uptake, membrane GLUT4, phosphorylation-related proteins, and adipokines provides a mechanistic framework for studying adipocyte insulin sensitivity, while remaining limited by its in vitro model.
-
ER-Targeted EISA and Selective Cancer Cell Fate
2026-08-29
The reference study develops an alkaline phosphatase-responsive peptide that self-assembles at the endoplasmic reticulum of cancer cells. By combining enzyme-instructed self-assembly with p-toluenesulfonamide-mediated ER targeting, the authors enhanced ER stress and selectively induced apoptosis and necroptosis at lower effective concentrations.
-
Lysis Buffer for Reliable Mouse Genotyping
2026-08-28
Improve mouse genotyping workflows with a lysis buffer designed for rapid tissue digestion and PCR-ready genomic DNA release. This practical guide covers workflow setup, assay decisions, optimization parameters, and troubleshooting for tail, toe, and ear samples.